English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The structures of the novel acyl-enzyme fibrinolytic agents BRL 26920 and BRL 26921 are given. A model of venous thrombosis in which thromboplastin-induced thrombi are formed in the inferior vena cava of the rabbit is described. Thrombi were held in place by an implanted woollen thread and thrombolysis was measured by release of 125I-FDP into the circulation and by radiochemical quantitation of residual clots. BRL 26920 was compared with the same dose of activator-free human plasmin in the model. The acyl form of the enzyme was found to be significantly more active and caused significantly less disturbance of haemostasis than the free enzyme. Release of radioactivity from labelled thrombi suggested that the duration of fibrinolysis following a bolus of BRL 26920 was at least 4 hours.  Similar comparisons of BRL 26921 with unmodified streptokinase human plasminogen activator complexes were made in this model. Although neither agent caused large haemostatic changes the acyl-enzyme was significantly more active.

thrombosis and haemostasis

The Thrombolytic Activities In A Rabbit Model Of Venous Thrombosis Of An Acyl Human Plasmin Derivative (BRL 26920) And An Acyl Streptokinase Human Plasminogen Activator Complex (Brl 26921)